High CXCR3 on Leukemic Cells Distinguishes IgHV^mut from IgHV^unmut in Chronic Lymphocytic Leukemia: Evidence from CD5^high and CD5^low Clones

Table 1

Patient demographic and clinical characteristics.

Parameter	CLL ()
Age, years, median (min-max)	67 (50-86)
Gender (male/female)	35/25
Binet stage (A/B/C)	26/23/11
IgHV gene mutational status (mutated/unmutated)	24/36
Genetics
11q-/17p-	13/6
N/O	6/46
Not determined	2
Follow-up time months (mean, min–max)	53 (0-160)
Treatment history (yes/no)	29/31
Time of last treatment in treated patients (in respect to the sampling time) months (mean, min–max)	23 (1-61)
Time to the next treatment (in respect to the sampling time) months (mean, min–max)	29 (0-49)
CLL cells in peripheral blood
Percentage, mean (95% CI)	69.3 (62.3-76.3)
Absolute number (×10^9/L), mean (95% CI)	49.1 (32.3-65.9)

IgHV mutational status was defined as follows: IgHV^unmut with a cut-off of 2% deviation or >98% sequence identity to germline in the IgHV sequence (13). 11q- and 17p-: any FISH or karyotypic abnormality involving 11q or 17p; N: no detectable cytogenetic aberration by FISH; O: other cytogenetic abnormality (excluding 11q- or 17p-).